Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Guardant Health, Inc.NASDAQ: GH

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$112.5M, compared with -$82.24M a year earlier. Trailing-twelve-month EBITDA was -$441.45M.

Context

  • EBITDA amounted to 38.1% of revenue in FY2025, down 14.7 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 19 analysts of -$366.94M (+1.9%) for the fiscal year ending Dec 2026, a slowdown from the +4.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$112.5M-3.2% QoQ
Last fiscal yearDec 2025
-$373.91M+4.2% YoY
LTMSep 2026
-$441.45M-24.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.8%+26.3%+63.1 pp
1 year+4.2%+1.9%-2.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(373.91M) USD
Year-over-year change
+4.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How GH compares with its peers on the latest reported figures

  • GH's LTM Sep 2026 EBITDA of -$441.45M is the lowest of the 10 companies compared; the peer median is -$58.51M.
  • Its year-over-year change of -24.7% is the 7th highest of 10, against a peer median of +10.8%.
  • EBITDA amounts to 34.5% of revenue for GH, versus a peer median of 18.3%.
GH Competitors Peer median
EBITDA for GH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLLNBillionToOne, Inc.LTM Jun 2026$50.25M +362.6%—12.6%
NEONeoGenomics, Inc.LTM Jun 2026$12.89M +145.3%—1.7%
CSTLCastle Biosciences, Inc.LTM Mar 2026-$725.67K -101.8%—0.2%
BDSXBiodesix, Inc.LTM Mar 2026-$18.34M +33.2%—19.1%
FLGTFulgent Genetics, Inc.LTM Mar 2026-$58.51M -133.4%—18.3%
PSNLPersonalis, Inc.LTM Mar 2026-$85.53M -16.7%—132.6%
NTRANatera, Inc.LTM Jun 2026-$178.71M +15.6%—6.6%
MYGNMyriad Genetics, Inc.LTM Mar 2026-$334.2M -423.0%—40.3%
GRALGRAIL, Inc.LTM Jun 2026-$374.1M +10.8%—226.4%
GHGuardant Health, Inc.LTM Sep 2026-$441.45M -24.7%—34.5%
Peer median (excluding GH) -$58.51M+10.8%—18.3%

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue373.65M449.54M563.95M739.02M982.02M
Cost of Revenue122.91M156.33M227.05M289.8M349.01M
Gross Profit250.74M293.21M336.9M449.22M633.01M
Gross Margin67.1%65.2%59.7%60.8%64.5%
Research & Development263.22M373.81M367.19M347.75M364.19M
Selling, General & Admin398.52M463.78M451.03M545.06M706.07M
Operating Expenses661.74M837.59M901.62M892.81M1.07B
Depreciation & Amortization22.27M35.96M42.88M42.39M39.74M
EBITDA(359.62M)(614.91M)(433.31M)(390.12M)(373.91M)
EBITDA Margin-96.2%-136.8%-76.8%-52.8%-38.1%
Operating Income(411M)(544.38M)(564.73M)(443.59M)(437.25M)
Operating Margin-110.0%-121.1%-100.1%-60.0%-44.5%
Interest Income3.93M6.07M35.37M53.69M34.1M
Interest Expense2.58M2.58M2.58M2.58M3.9M
Other Income / Expenses26.53M(109.07M)85.96M8.51M19.71M
Income Before Tax(384.47M)(653.45M)(478.76M)(435.09M)(417.54M)
Pre-Tax Margin-102.9%-145.4%-84.9%-58.9%-42.5%
Income Tax Expense300K1.14M685K1.28M(1.26M)
Net Income(405.67M)(654.59M)(479.45M)(436.37M)(416.28M)
Net Margin-108.6%-145.6%-85.0%-59.0%-42.4%
EPS (Basic)(4.00)(6.41)(4.28)(3.56)(3.32)
EPS (Diluted)(4.00)(6.41)(4.28)(3.56)(3.32)
Weighted Avg Shares101.31M102.18M111.99M122.75M125.37M
Weighted Avg Shares (Diluted)101.31M102.18M111.99M122.75M125.37M

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.